Skip to main
EXAS
EXAS logo

Exact Sciences (EXAS) Stock Forecast & Price Target

Exact Sciences (EXAS) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Exact Sciences has raised its screening revenue guidance to $2.510-2.520 billion, reflecting an increase of $60 million at the midpoint, indicative of robust growth potential in its cancer screening market. The company's precision oncology revenue guidance has also been uplifted to $710-715 million, demonstrating a continued expansion of its genomic testing solutions. Additionally, the positive outlook is reinforced by an increase in adjusted EBITDA guidance to $470-480 million and expectations for continued market adoption of Cologuard, which is aimed at achieving over 40% market penetration in the long term.

Bears say

The financial performance of Exact Sciences has been challenged by its reliance on promotional marketing to drive demand for its Cologuard product, indicating sensitivity to fluctuations in marketing spending. Additionally, the company's history of net losses raises concerns about its ability to achieve and sustain GAAP profitability, with a projected growth impact of approximately 300-400 basis points in the fourth quarter. Compounding these issues, Exact's revenue estimates for 2027 remain below target, reflecting uncertainties related to competition and potential market dynamics.

Exact Sciences (EXAS) has been analyzed by 16 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exact Sciences (EXAS) Forecast

Analysts have given Exact Sciences (EXAS) a Buy based on their latest research and market trends.

According to 16 analysts, Exact Sciences (EXAS) has a Buy consensus rating as of Nov 7, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $73.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $73.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exact Sciences (EXAS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.